How have OKYO shares performed in 2024?

OKYO Pharma's stock was trading at GBX 1.40 at the beginning of 2024. Since then, OKYO stock has increased by 0.0% and is now trading at GBX 1.40. View the best growth stocks for 2024 here .

How do I buy shares of OKYO Pharma?

Shares of OKYO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. Compare Top Brokerages Here .

LON:OKYO

OKYO Pharma (OKYO) Share Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free OKYO Stock Alerts

GBX 1.40

-0.45 (-24.32%)

(As of 05/19/2023)

Compare

Today's Range: 1.40
▼
1.98
50-Day Range: 1.40
▼
1.40
52-Week Range: 1.35
▼
8.50

Volume: 364,142 shs
Average Volume: 431,999 shs
Market Capitalization: £23.24 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Headlines Insider Trades

Get OKYO Pharma alerts:

Ad Altimetry

I’m officially sounding the alarm.

AI has been the hottest financial story of 2023. And rightly so – AI stocks have beat the broader market by over 62%. But right now, my system is warning me that many AI stocks are riding higher on hype alone.

Just click here to watch my full uncensored interview.

About OKYO Pharma Stock (LON:OKYO)

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

OKYO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OKYO Stock News Headlines

April 17, 2024 | americanbankingnews.com

OKYO Pharma (LON:OKYO) Stock Price Down 24.3%

March 31, 2024 | msn.com

A second Kobayashi Pharma Japan factory inspected over deaths

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

March 31, 2024 | msn.com

Japanese authorities inspect second Kobayashi Pharma factory after deaths

March 30, 2024 | msn.com

Kobayashi factory searched over deaths possibly linked to supplements

March 29, 2024 | msn.com

5 dead and over 100 hospitalized from recalled Japanese health supplements

March 28, 2024 | msn.com

What are 'beni-koji' products linked to Japan deaths?

March 27, 2024 | msn.com

A Japanese supplement pill is recalled after two people died and more than 100 were hospitalized

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

March 14, 2024 | msn.com

Unicycive rises 4% on $50M private placement

March 3, 2024 | msn.com

People in Japan more worried about smell of others' excrement than their own: survey

February 23, 2024 | msn.com

1 in 4 Japan primary school kids with hay fever's itchy eyes have trouble studying

February 22, 2024 | benzinga.com

OKYO Pharma Stock (NASDAQ:OKYO), Short Interest Report

February 9, 2024 | msn.com

OKYO Pharma gains on receiving FDA nod of IND for OK-101 in neuropathic corneal pain

February 9, 2024 | morningstar.com

OKYO Shares Rise 12% After FDA Clearance for IND Application

January 8, 2024 | markets.businessinsider.com

OKYO Pharma Says Phase 2 Study Of OK-101 Did Not Meet Primary Goal

January 5, 2024 | finance.yahoo.com

OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024

December 4, 2023 | proactiveinvestors.com

Eyepoint Pharmaceuticals stock soars on wet-AMD trial results

December 4, 2023 | finance.yahoo.com

OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit

November 3, 2023 | msn.com

HC Wainwright & Co. Initiates Coverage of OKYO Pharma Limited - (OKYO) with Buy Recommendation

October 31, 2023 | proactiveinvestors.com

OKYO Pharma raises $5.84m via share issuance

October 31, 2023 | finanznachrichten.de

OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction

October 5, 2023 | msn.com

Dry Eye Disease Affects Around 50M Americans, OKYO Pharma's Candidate Shows Safety In Mid-Stage Study

October 5, 2023 | msn.com

OKYO shares retreat 12% after rallying ahead of Phase 2 study update

October 5, 2023 | markets.businessinsider.com

OKYO Pharma Reports Positive Safety Data Profile For OK-101 In Dry Eye Disease

October 5, 2023 | proactiveinvestors.com

OKYO Pharma phase II dry eye trial making encouraging progress

October 5, 2023 | finance.yahoo.com

OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED")

See More Headlines

Receive OKYO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OKYO Pharma and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: LON
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: LON:OKYO
CUSIP: N/A
CIK: N/A
Web: www.okyopharma.com
Phone: 44 20 7495 2379
Fax: N/A
Employees: 6
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): GBX (0.01)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: £-6,700,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -397.13%
Return on Assets: -154.72%

Debt

Debt-to-Equity Ratio: 1.65
Current Ratio: 0.83
Quick Ratio: 2.65

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: 28.00
Book Value: GBX (1) per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 1,660,000,000
Free Float: N/A
Market Cap: £23.24 million
Optionable: Not Optionable
Beta: -0.06

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Gary S. Jacob Ph.D. (Age 75)
CEO & Exec. Director
Comp: $311k
Mr. Michael Paul Beck (Age 65)
Founder
Ms. Keeren Shah (Age 45)
Chief Financial Officer
Dr. Rajkumar Patil Ph.D. (Age 64)
Chief Scientific Officer

Key Competitors

View All Competitors

OKYO Stock Analysis - Frequently Asked Questions

How have OKYO shares performed in 2024?: OKYO Pharma's stock was trading at GBX 1.40 at the beginning of 2024. Since then, OKYO stock has increased by 0.0% and is now trading at GBX 1.40.
View the best growth stocks for 2024 here.
How do I buy shares of OKYO Pharma?: Shares of OKYO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:OKYO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial